Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
Date:1/30/2009

ATHENS, Ga., Jan. 30 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its hN2(TM) cells commercially available to the research community in early 2009. The cells, derived from NIH registered human embryonic cell lines, are offered as a normal, consistent population of neural cells in an adherent monolayer format, a product never before offered to the research community. hN2 cells provide a human cell based format for research ranging from Alzheimer's to spinal cord injury and depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research and we are pleased to be able to offer these cells commercially to the research market," says David Ray, ArunA's Chief Executive Officer. "By offering our products through multi-national distribution partners, we will provide broad access to the unique tools that may accelerate the pace of neural research with more physiologically relevant cellular research models," Ray said.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, hNP1(TM) (ENSTem-A(TM)), is based on patented technology licensed from the University of Georgia. For more information, visit www.arunabiomedical.com.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
4. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
5. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
6. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
7. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
10. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
11. Environmental Tectonics Corporations BioMedical Division Announces New Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... BC, Canada (PRWEB) , ... July 20, 2017 , ... ... today announced the winning recipients of the 2017 IAC Awards at the 22nd World ... awards, the committee also named four faculty to receive the Distinguished Fellowship Awards. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... on digital pathology and artificial intelligence Tuesday, July 25, during the Association of ... from Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, will ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial Data Solutions (CDS) ... study participants truly unified. TrialKit, a native mobile app, empowers investigators and clinicians ... studies entirely on mobile devices. With TrialKit, clinical researchers can utilize Core Motion ...
(Date:7/18/2017)... Switzerland (PRWEB) , ... July 18, 2017 , ... ... R&D, today announced that Merck, a leading science and technology company, has implemented ... innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):